Literature DB >> 2945832

Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion.

R J Cody, S A Atlas, J H Laragh, S H Kubo, A B Covit, K S Ryman, A Shaknovich, K Pondolfino, M Clark, M J Camargo.   

Abstract

We investigated atrial natriuretic factor (ANF) in humans, measuring plasma immunoreactive (ir) ANF (in femtomoles per milliliter), and renal, hormonal, and hemodynamic responses to ANF infusion, in normal subjects (NL) and congestive heart failure patients (CHF). Plasma irANF was 11 +/- 0.9 fmol/ml in NL and 71 +/- 9.9 in CHF (P less than 0.01); the latter with twofold right ventricular increment (P less than 0.05). In NL, ANF infusion of 0.10 microgram/kg per min (40 pmol/kg per min) induced increases (P less than 0.05) of absolute (from 160 +/- 23 to 725 +/- 198 mueq/min) and fractional (1-4%) sodium excretion, urine flow rate (from 10 +/- 1.6 to 20 +/- 2.6 ml/min), osmolar (from 3.2 +/- 0.6 to 6.8 +/- 1.2 ml/min) and free water (from 6.8 +/- 1.6 to 13.6 +/- 1.6 ml/min) clearances, and filtration fraction (from 20 +/- 1 to 26 +/- 2%). Plasma renin and aldosterone decreased 33% and 40%, respectively (P less than 0.01). Systolic blood pressure fell (from 112 +/- 3 to 104 +/- 5 mmHg, P less than 0.05) in seated NL; but in supine NL, the only hemodynamic response was decreased pulmonary wedge pressure (from 11 +/- 1 to 7 +/- 1 mmHg, P less than 0.05). In CHF, ANF induced changes in aldosterone and pulmonary wedge pressure, cardiac index, and systemic vascular resistance (all P less than 0.05); however, responses of renin and renal excretion were attenuated. ANF infusion increased hematocrit and serum protein concentration by 5-7% in NL (P less than 0.05) but not in CHF.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2945832      PMCID: PMC423836          DOI: 10.1172/JCI112723

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Atrial natriuretic factor inhibits vasotocin-induced water reabsorption in the toad urinary bladder.

Authors:  W K Samson; J C Vanatta
Journal:  Proc Soc Exp Biol Med       Date:  1986-01

2.  Actions of synthetic atrial natriuretic factor on bovine adrenal glomerulosa.

Authors:  T L Goodfriend; M E Elliott; S A Atlas
Journal:  Life Sci       Date:  1984-10-15       Impact factor: 5.037

3.  The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties.

Authors:  T G Flynn; M L de Bold; A J de Bold
Journal:  Biochem Biophys Res Commun       Date:  1983-12-28       Impact factor: 3.575

4.  Inhibition of aldosterone production by an atrial extract.

Authors:  K Atarashi; P J Mulrow; R Franco-Saenz; R Snajdar; J Rapp
Journal:  Science       Date:  1984-06-01       Impact factor: 47.728

5.  Ca-dependent hemodynamic and natriuretic effects of atrial extract in isolated rat kidney.

Authors:  M J Camargo; H D Kleinert; S A Atlas; J E Sealey; J H Laragh; T Maack
Journal:  Am J Physiol       Date:  1984-04

6.  Some statistical methods useful in circulation research.

Authors:  S Wallenstein; C L Zucker; J L Fleiss
Journal:  Circ Res       Date:  1980-07       Impact factor: 17.367

7.  Purification, sequencing and synthesis of natriuretic and vasoactive rat atrial peptide.

Authors:  S A Atlas; H D Kleinert; M J Camargo; A Januszewicz; J E Sealey; J H Laragh; J W Schilling; J A Lewicki; L K Johnson; T Maack
Journal:  Nature       Date:  1984 Jun 21-27       Impact factor: 49.962

8.  Bioactive cardiac substances: potent vasorelaxant activity in mammalian atria.

Authors:  M G Currie; D M Geller; B R Cole; J G Boylan; W YuSheng; S W Holmberg; P Needleman
Journal:  Science       Date:  1983-07-01       Impact factor: 47.728

9.  Specific receptor-mediated inhibition by synthetic atrial natriuretic factor of hormone-stimulated steroidogenesis in cultured bovine adrenal cells.

Authors:  A De Léan; K Racz; J Gutkowska; T T Nguyen; M Cantin; J Genest
Journal:  Endocrinology       Date:  1984-10       Impact factor: 4.736

10.  Reduction of cardiovascular disease events by worksite hypertension treatment.

Authors:  M H Alderman; S Madhavan; T Davis
Journal:  Hypertension       Date:  1983 Nov-Dec       Impact factor: 10.190

View more
  107 in total

Review 1.  Renal and hormonal abnormalities in chronic obstructive pulmonary disease (COPD).

Authors:  P Palange
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

Review 2.  Evidence based cardiology: prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction.

Authors:  R S McKelvie; C R Benedict; S Yusuf
Journal:  BMJ       Date:  1999-05-22

Review 3.  Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.

Authors:  Lincoln R Potter
Journal:  Pharmacol Ther       Date:  2010-12-24       Impact factor: 12.310

4.  Effects of atrial natriuretic peptide on systemic and renal hemodynamics and renal excretory function in patients with chronic renal failure.

Authors:  H Meyer-Lehnert; T Bayer; H G Predel; K Glänzer; H J Kramer
Journal:  Klin Wochenschr       Date:  1991-11-26

5.  A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension.

Authors:  Paul M McKie; Alessandro Cataliotti; Guido Boerrigter; Horng H Chen; S Jeson Sangaralingham; Fernando L Martin; Tomoko Ichiki; John C Burnett
Journal:  Hypertension       Date:  2010-10-25       Impact factor: 10.190

Review 6.  Nesiritide for acute decompensated heart failure: does the benefit justify the risk?

Authors:  Jonathan Sackner-Bernstein; Keith D Aaronson
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

7.  Effect of human atrial natriuretic peptide on blood glucose concentrations and hormone stimulation during insulin-induced hypoglycaemia in healthy man.

Authors:  E Jungmann; C Konzok; E Höll; W Fassbinder; K Schöffling
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

8.  Pulmonary vasorelaxant activity of atrial natriuretic peptide and brain natriuretic peptide in humans.

Authors:  R I Cargill; B J Lipworth
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

9.  Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.

Authors:  M Mukoyama; K Nakao; K Hosoda; S Suga; Y Saito; Y Ogawa; G Shirakami; M Jougasaki; K Obata; H Yasue
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

10.  Renal and hormonal effects and tolerance of an ANP analogue in healthy man.

Authors:  H Eiskjaer; M Schmiegelow; B Jespersen; I N Tietze; J D Jensen; S S Sørensen; K Thomsen; E B Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.